Abstract
Paliperidone is an antipsychotic recently made available in the US and UK in a special oral extended release form. Paliperidone is a modified form of risperidone namely 9-hydroxyrisperidone, (itself the active metabolite of risperidone). Since risperidone has been available for many years some argue that paliperidone is not a novel antipsychotic but a newly marketed variant. An injectable form, paliperidone palmitate is being trialled. Paliperidone is mainly excreted renally and there is only limited hepatic metabolism. Paliperidone works by partially blocking D2 dopamine receptors and fully blocking serotonin. The normal dosing range for paliperidone is 3-12 mg daily. Efficacy studies with paliperidone indicate that it is effective against schizophrenia and also has a similar side effect profile compared to other antipsychotics. There is an absence of effects on glucose and lipids in comparison with olanzapine. Symptom reduction in schizophrenia occurs as soon as day four of treatment with paliperidone. Clinical experience with risperidone over many years suggests that paliperidone would have a valuable role as an antipsychotic. The entity is not truly novel, but rather than being a variant existing purely for marketing purposes, should be regarded as an upgrade.
Keywords: Paliperidone, antipsychotic, active metabolite, Clinical Review, hepatic metabolism, serotonin, schizophrenia
Current Drug Therapy
Title: Paliperidone: A Clinical Review
Volume: 4 Issue: 1
Author(s): Ben Green
Affiliation:
Keywords: Paliperidone, antipsychotic, active metabolite, Clinical Review, hepatic metabolism, serotonin, schizophrenia
Abstract: Paliperidone is an antipsychotic recently made available in the US and UK in a special oral extended release form. Paliperidone is a modified form of risperidone namely 9-hydroxyrisperidone, (itself the active metabolite of risperidone). Since risperidone has been available for many years some argue that paliperidone is not a novel antipsychotic but a newly marketed variant. An injectable form, paliperidone palmitate is being trialled. Paliperidone is mainly excreted renally and there is only limited hepatic metabolism. Paliperidone works by partially blocking D2 dopamine receptors and fully blocking serotonin. The normal dosing range for paliperidone is 3-12 mg daily. Efficacy studies with paliperidone indicate that it is effective against schizophrenia and also has a similar side effect profile compared to other antipsychotics. There is an absence of effects on glucose and lipids in comparison with olanzapine. Symptom reduction in schizophrenia occurs as soon as day four of treatment with paliperidone. Clinical experience with risperidone over many years suggests that paliperidone would have a valuable role as an antipsychotic. The entity is not truly novel, but rather than being a variant existing purely for marketing purposes, should be regarded as an upgrade.
Export Options
About this article
Cite this article as:
Green Ben, Paliperidone: A Clinical Review, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081903
DOI https://dx.doi.org/10.2174/157488509787081903 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Traffic in the Operating Room: A Review of Factors Influencing Air Flow and Surgical Wound Contamination.
Infectious Disorders - Drug Targets Genetic Insights into Sporadic Parkinson's Disease Pathogenesis
Current Genomics Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures
Current Molecular Pharmacology Structure, Substrate Complexation and Reaction Mechanism of Bacterial Asparaginases
Current Chemical Biology Inhibition of Voltage-Gated Calcium Channels by RGK Proteins
Current Molecular Pharmacology Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research Microemulsion Systems: Prospective Approach for Superior Drug Delivery
Drug Delivery Letters Delayed Neuroleptic Malignant Syndrome Associated with the Use of Low Dose Risperidone in Conjunction with Cholinergic Drugs-the Dangers of Polypharmacy in the Elderly
Current Drug Therapy Therapeutics and Carriers: The Dual Role of Proteins in Nanoparticles for Ocular Delivery
Current Topics in Medicinal Chemistry Target Sites for the Design of Anti-trypanosomatid Drugs Based on the Structure of Dihydroorotate Dehydrogenase
Current Pharmaceutical Design Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Hypocretin/Orexin Neuropeptides: Participation in the Control of Sleep- Wakefulness Cycle and Energy Homeostasis
Current Neuropharmacology Enhanced Action Potential Passage Through the Node of Ranvier of Myelinated Axons via Proton Hopping
Current Computer-Aided Drug Design Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Disorders of Primary Metabolites in Response to Drought May Increase the Synthesis of Natural Products for Medicinal Purposes: South American Herbs - a Case Study
Recent Patents on Biotechnology Clinical Applications of MAO-Inhibitors
Current Medicinal Chemistry FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology